Abstract
The concept of conditional pharmacology as initially elucidated by Dr Michael Whitehouse and his colleagues from their studies of drug-disease interactions has broad import in a rational drug discovery and development programme. The concept can be extended to toxicology and thus can be viewed as encompassing virtually all means and methods of discovering and enhancing the efficacy, while reducing the toxicity of drugs and biologics. The concept involves employing the physiological or metabolic activity, genetic and/or molecular structure of the host, of the disease process and/or of the parasite to activate and target the drug or biologic, as well as to regulate and delimit its activity. Thus, the concept not only applies to the treatment of inflammatory diseases, but also to the treatment of neoplastic and infectious diseases, to facilitating wound healing, and is in fact an underlying assumption, and expected consequence, of successful gene therapy. The concept applies to clinical studies as well, arguing for more pharmacokinetic and chrono-pharmacological studies in the early phases of clinical testing and the inclusion in later-stage clinical trials of more diverse populations, as regards age, gender and ethnicity, if the indication warrants. Facilitating and monitoring compliance, post- as well as pre-market approval, also are critical components of the fully implemented concept.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Powanda MC, Canonico PG, eds. Infection: The Physiologic and Metabolic Response of the Host. Amsterdam:Elsevier/North Holland Publishing Company; 1981.
Chen LC, Scrimshaw NS, eds. Diarrhea and Malnutrition: Interactions, Mechanisms and Interventions. New York: Plenum Publishing; 1982.
Oberbauer R, Krivaek P, Turnheim K. Pharmacokinetics of indomethacin in the elderly. Clin Pharmacokinet. 1993;24:428–34.
Rho JP, Castle S, Smith K, Bawdon RE, Normal DC. Effect of age and renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam. Drug Invest. 1993;6:303–10.
Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL, Powell JR. Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin Pharmacol Ther. 1992;51:51–5.
Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994;15:619–29.
Lang CC, Stein M, Brown RM, et al. Attenuation of isoproterenol-mediated vasodilation in blacks. N Engl J Med. 1995;333:155–60.
Hrushesky WJM, Langer R, Theeuwes F. Temporal control of drug delivery. Ann NY Acad Sci. 1991;618:1–641.
Lévi F, Metzger G, Deprés-Brummer P. Implications of biological rhythms for toxicology. Drug Inform J. 1994;28:15–202.
Whitehouse MW. Disease-drug interactions: utility of the conditional concept for experimental pharmacology and toxicology in the context of inflammation. In: Rainsford KD, Velo GP, eds. Side-Effects of Anti-Inflammatory Drugs. Lancaster: MTP Press; 1987;1:259–74.
Whitehouse MW, Vernon-Roberts B. Conditional pharmacology: expression of anti-inflammatory activity may require pre-existent inflammatory mediators/hormones. Inflammopharmacology. 1991;1:61–8.
Whitehouse MW. Disease-drug interactions: significance or insignificance of the ED50 value for anti-inflammatory agents. Inflammopharmacology. 1991;1:143–9.
Powanda MC, Cockerell GL, Moe JB, Abeles FB, Pekarek RS, Canonico PG. Induced metabolic sequelae of tularemia in the rat: correlation with tissue damage. Am J Physiol. 1975;229:479–83.
Powanda MC. Changes in body balances of nitrogen and other key nutrients: description and underlying mechanisms. Am J Clin Nutr. 1977;30:1254–68.
Powanda MC, Abeles FB, Bostian KA, Fowler JP, Hauer EC. Differential effect of clofibrate on inflammation-induced alterations in plasma proteins in the rat. Biochem J. 1979;178:633–41.
Powanda MC, Moyer ED. Plasma proteins and wound healing. Surg Gynecol Obstet. 1981;153:749–55.
Powanda MC. Conference perspective: biologic agents in autoimmune diseases IV. Inflammopharmacology. 1995;3:201–11.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Powanda, M.C. (1997). The Concept of Conditional Pharmacology and Toxicology. In: Rainsford, K.D. (eds) Side Effects of Anti-Inflammatory Drugs IV. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5394-2_11
Download citation
DOI: https://doi.org/10.1007/978-94-011-5394-2_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6269-5
Online ISBN: 978-94-011-5394-2
eBook Packages: Springer Book Archive